DE69718915D1 - Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose - Google Patents

Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose

Info

Publication number
DE69718915D1
DE69718915D1 DE69718915T DE69718915T DE69718915D1 DE 69718915 D1 DE69718915 D1 DE 69718915D1 DE 69718915 T DE69718915 T DE 69718915T DE 69718915 T DE69718915 T DE 69718915T DE 69718915 D1 DE69718915 D1 DE 69718915D1
Authority
DE
Germany
Prior art keywords
arthrosis
syndrome
treatment
rheumatoid
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69718915T
Other languages
English (en)
Other versions
DE69718915T2 (de
Inventor
Ernir Snorrason
James Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69718915D1 publication Critical patent/DE69718915D1/de
Application granted granted Critical
Publication of DE69718915T2 publication Critical patent/DE69718915T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69718915T 1996-02-19 1997-02-19 Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose Expired - Fee Related DE69718915T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS4325 1996-02-19
GBGB9606736.8A GB9606736D0 (en) 1996-02-19 1996-03-29 Therapeutic method
PCT/IS1997/000001 WO1997029750A1 (en) 1996-02-19 1997-02-19 Treatment of arthritis disorders, rheumatoid arthritis and manifestations associated with rheumatoid disorders

Publications (2)

Publication Number Publication Date
DE69718915D1 true DE69718915D1 (de) 2003-03-13
DE69718915T2 DE69718915T2 (de) 2003-12-11

Family

ID=36764777

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69718915T Expired - Fee Related DE69718915T2 (de) 1996-02-19 1997-02-19 Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose

Country Status (11)

Country Link
US (1) US6358941B1 (de)
EP (1) EP0918523B1 (de)
AT (1) ATE232102T1 (de)
AU (1) AU2105997A (de)
CA (1) CA2251114C (de)
DE (1) DE69718915T2 (de)
DK (1) DK0918523T3 (de)
ES (1) ES2192667T3 (de)
GB (1) GB9606736D0 (de)
HK (1) HK1020535A1 (de)
WO (1) WO1997029750A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008672A1 (en) * 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
IT1304904B1 (it) * 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
WO2002094321A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
US20050260613A1 (en) * 2003-10-28 2005-11-24 Genaissance Pharmaceuticals LRPAP1 genetic markers associated with galantamine
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
EP2518510A1 (de) * 2004-04-20 2012-10-31 SphingoTec GmbH Verwendung von Vorläufern von Tachykinine und/oder deren Fragmenten in der medizinischen Diagnose
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
EP1807087A2 (de) 2004-10-12 2007-07-18 Ernir Snorrason Inhibitoren von acetylcholinesterase zur behandlung von hauterkrankungen
US8193212B2 (en) * 2005-05-23 2012-06-05 President And Fellows Of Harvard College Use of huperzine for neuropathic pain
CN101190330A (zh) * 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
FR2912841B1 (fr) * 2007-02-15 2009-05-22 Soitec Silicon On Insulator Procede de polissage d'heterostructures
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
CA2736114A1 (en) * 2008-09-04 2010-03-11 President And Fellows Of Harvard College Treatment of neurological disorders using huperzine
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
CN102573848A (zh) * 2009-04-24 2012-07-11 济州大学校产学协力团 含有去甲加兰他敏化合物作为活性成分的用于预防和治疗脱发症的组合物
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
BR112012019923A2 (pt) 2010-02-09 2016-08-09 Univ Johns Hopkins métodos e composições para melhorar a função cognitiva
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
EP2640378A4 (de) * 2010-11-18 2014-05-21 Envivo Pharmaceuticals Inc Behandlung von entzündungen mit bestimmten alpha-7-nikotinsäurerezeptoragonisten in kombination mit acetylcholinesterasehemmern
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
EP3265127B1 (de) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepriston und octreotid zur verwendung bei der behandlung des cushing-syndroms bei einem patienten mit einem adrenocorticotropen hormon (acth) sezernierenden pankreatischen neuroendokrinen tumor
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
US11045482B2 (en) 2017-03-09 2021-06-29 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
CN109200051A (zh) * 2017-07-03 2019-01-15 南京和博生物医药有限公司 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
WO2023070351A1 (zh) * 2021-10-27 2023-05-04 香港理工大学 通过抑制乙酰胆碱酯酶来预防和治疗骨关节疾病

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US661509A (en) * 1900-09-04 1900-11-13 John S Fogg Traveler's hat-conformer.
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer

Also Published As

Publication number Publication date
GB9606736D0 (en) 1996-06-05
ATE232102T1 (de) 2003-02-15
DK0918523T3 (da) 2003-05-26
DE69718915T2 (de) 2003-12-11
ES2192667T3 (es) 2003-10-16
HK1020535A1 (en) 2000-05-12
AU2105997A (en) 1997-09-02
CA2251114A1 (en) 1997-08-21
EP0918523A1 (de) 1999-06-02
EP0918523B1 (de) 2003-02-05
CA2251114C (en) 2007-10-02
US6358941B1 (en) 2002-03-19
WO1997029750A1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
DE69718915T2 (de) Behandlung von arthrose, rheumatoider arthrose und erscheinungen verwandt an arthrose
MD809C2 (ro) (-)-Enantiomer cis-4-amino-1-(2-hidroximetil -1,3-oxatiolan-5-il)-(1H)-pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer şi (Ş)-enantiomer, procedeu de obţinere a lor, compoziţie antivirotică şi procedeu de tratament al mamiferelor, inclusiv al omului, ce suferă de infecţii virotice sau sunt susceptibile faţă de aceste infecţii
TR200001982T2 (tr) Farmasötik vurulu salınımlı oral dozaj şekli.
MY115638A (en) N-substituted heterocyclic derivatives, their preparation and pharmaceutical compositions containing them
EA200100872A1 (ru) Композиция валдекоксиба
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
ATE311903T1 (de) Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
DE69520364D1 (de) Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate-aufnahme
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
ATE63813T1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
IL112664A (en) 4-amino derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
MD960288A (ro) Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare
JP2002523370A5 (de)
MD1838G2 (ro) Derivaţi de 5,6-diclorbenzimidazol, procedeu de obţinere a lor, compoziţie farmaceutică şi metodă de tratament sau de prevenire a infecţiei virotice herpetice
BE902874A (fr) Compositions therapeutiques et procede pour le traitement ou la prevention des maladies provoquees par le paf-acether
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
DE69033970D1 (de) Huperzin a analoge verbindungen
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
PT1007040E (pt) Utilizacao de fanquinona no tratamento da doenca de alzheimer
MD940152A (ro) Compoziţie farmaceutică pentru tratarea infecţiilor şi bolilor, provocate de virusul hepatitei V (HBV)
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
BG103512A (en) Substituted pyramidine compounds and their application
DE69128254D1 (de) Antihypertensive benzopyran-derivate
DE69819922D1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee